Global Market Development Lead, Mevrometostat

At Pfizer Oncology, we are committed to “Outdo Cancer” by advancing transformative medicines wherever we can make a profound difference in the lives of patients. Pfizer Oncology is focused on extending its leadership in genitourinary cancers and we are committed to developing and delivering a broad portfolio of medicines in prostate cancer that define standards of care for patients across the treatment continuum.  Mevrometostat is a first-in-class, , small-molecule EZH2 inhibitor in Phase-3 development for the treatment of advanced prostate cancer (aPC).  There are currently 3 on going Phase 3 trials with readouts expected in 2026, 2027 & 2028. When used in combination with androgen receptor pathway inhibitors (ARPIs; like XTANDI), Mevrometostat may overcome ARPI resistance- a common cause of PC disease progression.  Prostate cancer is the 2nd most common cancer in men worldwide and the 5th most common cause of cancer death among men, mCRPC represents an addressable patient population of ~52,000 patients in the US.  In addition to the Phase 3 trials, we continue to evaluate further development opportunities for Mevrometostat in earlier lines of prostate cancer.

ROLE SUMMARY

As a first in its class EZ-H2 inhibitor in prostate cancer, Mevrometostat is well positioned to drive the narrative and value of EZH2 inhibition in PC .  The Market Development Lead will be responsible for designing and launching a robust commercial market development plan that will enable Pfizer to define this new class of treatment & establish EZH2 as viable target in metastatic prostate cancer.  Historically, HCPs have been slow to adopt new SoC therapies in PC , therefore success will be rooted in overcoming strong adoption hesitancy and putting forth a clear and compelling understanding of EZH2 and its differentiation proposition from other treatment options both within class and across classes.  These activities when done successfully can significantly impact the commercial success of mevrometostat by generating excitement about this new target, therefore optimizing the EZH2i initial uptake and peak class share.

Mevrometostat’s arrival will also become a powerful opportunity to illuminate and position Pfizer as a commanding leader in Prostate Cancer.   Building on an already a strong existing portfolio of products (Xtandi, Orgoyvx (US Only) +  Talzena Globally) and  now with Mevrometostat’ s arrival, this becomes a marquee opportunity to bolster Pfizer’s already strong heritage.  Leveraging a clear co-positioning  strategy as the roadmap, the market development lead will be  critical partner in developing  the portfolio leadership approach in order to clearly express the depth and breadth of the many unmet needs our products support in Prostate Cancer. These efforts not only strengthen reasons to believe in our prostate portfolio but will buoy the credibility and reasons to believe in our new launch as well. 

Our market development efforts are critical and therefore the selected candidate will need to understand not only the launch excellence process, but also be  attuned to identifying and understanding key mPC market dynamics in order to hone in on deep & robust insights that will drive needed behavior changes.   The candidate should have a proven track record of working in a matrix team environment, with multiple regional, marketing, and cross-functional partners.

ROLE RESPONSIBILITIES

• Lead our pre-launch strategic market development efforts to both strengthen understanding and awareness of this very new and innovative MOA (the key role EZH2 plays in prostate cancer) to all critical key stakeholders and target audiences

• Build and execute a compelling unbranded campaign and a strong market development tactical plan to support  this effort

• Design and map a robust market development  promotional plan from omnichannel, to medical education to congress engagement and define investment priority

• Ensure coordination of the market development strategy at the global, regional and local levels and ensure consistency of approach and implementation

• Determine the longer term strategy evolutionary needs  of our market development efforts as the brand approaches earlier line indications (~2028) for an mCSPC indication.    

• Set market development engagement priorities by stakeholder (HCP/Oncology/Urology/Nurses/Payers and Patients)

• Partner across the portfolio asset teams to identify approaches for optimally expressing Pfizer Leadership Narrative in Prostate Cancer

•   Leverage our co-positioning strategy efforts as a springboard to identify and articulate Pfizer’s support for HCPs/Patients across the mPC continuum

•  Ensure our PC leadership arc narrative and messages are aligned to work within the umbrella of a broad